View the PDF

Includes: Fourth annual Prostaid Calgary Picnic, Gene Therapy CAN-2409 Plus EBRT Improves Prostate Cancer-Specific DFS, ArteraAI Pathology Test Launches for Personalizing Prostate Cancer Therapy, Study finds prostate cancer overdiagnosis rises sharply with age, Urocross Expander demonstrates sustained LUTS improvement through 24 months in pivotal BPH trial, Experimental drug shows promise for some patients with advanced prostate cancer, Testosterone Therapy Ups Sexual Desire, Activity After Low Grade Prostate Cancer Surgery, and more.